XML 94 R21.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2014
Summary of Fair Value Measurement Financial Asset and Liabilities | Financial assets and liabilities subject to fair value measurements were as follows (in thousands):
|  | Fair Value Measurements at December 31, 2014 |
|  |  |  |  | Quoted Prices in Active Markets for Identical Assets |  |  | Significant Other Observable Inputs |  |  | Significant Unobservable Inputs |
|  | Total |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 131,545 |  |  | $ | 131,545 |  |  | $ | — |  |  | $ | — |
Money market funds |  |  | 26,046 |  |  |  | 26,046 |  |  |  | — |  |  |  | — |
Restricted cash |  |  | 300 |  |  |  | 300 |  |  |  | — |  |  |  | — |
Total Assets |  | $ | 157,891 |  |  | $ | 157,891 |  |  | $ | — |  |  | $ | — |
|  | Fair Value Measurements at December 31, 2013 |
|  |  |  |  | Quoted Prices in Active Markets for Identical Assets |  |  | Significant Other Observable Inputs |  |  | Significant Unobservable Inputs |
|  | Total |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 90,434 |  |  | $ | 90,434 |  |  | $ | — |  |  | $ | — |
Money market funds |  |  | 26,047 |  |  |  | 26,047 |  |  |  | — |  |  |  | — |
Restricted cash |  |  | 405 |  |  |  | 405 |  |  |  | — |  |  |  | — |
Total Assets |  | $ | 116,886 |  |  | $ | 116,886 |  |  | $ | — |  |  | $ | — |
Estimated Useful Lives | Repairs and maintenance costs are expensed as incurred. Depreciation is computed using the straight-line method over the following estimated useful lives:
Computer equipment |  | 3 years
Software |  | 3 years
Furniture |  | 10 years
Laboratory and office equipment |  | 5 years
Leasehold improvements |  | Shorter of lease term or useful life
Computation of Basic and Diluted Income (Loss) Per Common Share | Basic and diluted income (loss) per common share is computed as follows (in thousands except share and per share data):
|  | Year Ended December 31, |
|  | 2014 |  |  | 2013 |  |  | 2012 |
Net income (loss) |  | $ | (38,313 | ) |  | $ | (261 | ) |  | $ | 8,362 |
Less: undistributed earnings allocated to participating securities |  |  | — |  |  |  | — |  |  |  | (8,362 | )
Net income (loss) allocable to common shares |  | $ | (38,313 | ) |  | $ | (261 | ) |  | $ | — |
Basic weighted average common shares outstanding |  |  | 27,384,990 |  |  |  | 6,847,697 |  |  |  | 1,083,276 |
Basic income (loss) per common share |  | $ | (1.40 | ) |  | $ | (0.04 | ) |  | $ | 0.00 |
Net income (loss) |  | $ | (38,313 | ) |  | $ | (261 | ) |  | $ | 8,362 |
Less: undistributed earnings allocated to participating securities and other add-backs to net income (loss) |  |  | — |  |  |  | — |  |  |  | (8,362 | )
Net income (loss) allocable to common shares |  | $ | (38,313 | ) |  | $ | (261 | ) |  | $ | — |
Basic weighted average common shares outstanding |  |  | 27,384,990 |  |  |  | 6,847,697 |  |  |  | 1,083,276 |
Effect of dilutive securities |  |  | — |  |  |  | — |  |  |  | — |
Diluted weighted average common shares outstanding |  |  | 27,384,990 |  |  |  | 6,847,697 |  |  |  | 1,083,276 |
Diluted income (loss) per common share |  | $ | (1.40 | ) |  | $ | (0.04 | ) |  | $ | 0.00 |
Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Income (Loss) Per Share | The following common stock equivalents were excluded from the calculation of diluted net income (loss) per share because their effect would be anti-dilutive:
|  | Year Ended December 31, |
|  | 2014 |  |  | 2013 |  |  | 2012 |
Series A-1 Preferred Stock |  |  | — |  |  |  | — |  |  |  | 2,156,114 |
Series A-2 Preferred Stock |  |  | — |  |  |  | — |  |  |  | 392,274 |
Series B Preferred Stock |  |  | — |  |  |  | — |  |  |  | 4,336,037 |
Series C Preferred Stock |  |  | — |  |  |  | — |  |  |  | 5,909,906 |
Series D Preferred Stock |  |  | — |  |  |  | — |  |  |  | 769,468 |
Series D-2 Preferred Stock |  |  | — |  |  |  | — |  |  |  | 3,391,991 |
Effect of Converted Preferred Stock |  |  | — |  |  |  | 13,189,920 |  |  |  | — |
Warrants to purchase Series D-2 Preferred Stock |  |  | — |  |  |  | — |  |  |  | 180,784 |
Stock Options |  |  | 2,094,904 |  |  |  | 2,313,970 |  |  |  | 3,249,702 |
Summary of Significant Revenue [Member] |
Summary of Percentage of Customer Concentration | The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:
|  | Year Ended December 31, |
|  | 2014 |  |  | 2013 |  |  | 2012 |
Servier |  |  | 36.4 | % |  |  | 51.6 | % |  |  | 17.3 | %
Boehringer |  |  | 28.6 | % |  |  | 24.8 | % |  |  | 18.4 | %
Takeda |  |  | 16.8 | % |  |  | — |  |  |  | — |
Gilead |  |  | 11.4 | % |  |  | 13.8 | % |  |  | — |
Eli Lilly |  |  | 0.9 | % |  |  | 1.4 | % |  |  | 48.9 | %
Summary of Significant Accounts Receivable[Member] |
Summary of Percentage of Customer Concentration | The following table includes those collaborators that represent more than 10% of accounts receivable at the date indicated:
|  | December 31, |
|  | 2014 |  |  | 2013 |
Servier |  |  | 33.3 | % |  |  | 6.4 | %
Boehringer |  |  | 21.2 | % |  |  | 12.2 | %
Green Cross |  |  | 17.9 | % |  |  | — |
Gilead |  |  | — |  |  |  | 53.4 | %
Pfizer |  |  | — |  |  |  | 12.3 | %

X
- Definition Property plant and equipment estimated useful life. + References No definition available. + Details
Name: | mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock
Namespace Prefix: | mgnx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a,b,bb) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2C -URI http://asc.fasb.org/extlink&oid=36462937&loc=SL7498348-110258 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |